Gene therapy for spinomuscular atrophy: A biomedical advance, a missed opportunity for more equitable drug pricing

Gene Therapy

Volumn 24, Issue 9, 2017, Pages 503-505

  Friedmann, T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GENE THERAPY AGENT;

ANTISENSE THERAPY; DISEASE MODEL; DRUG COST; GENE THERAPY; HUMAN; NONHUMAN; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; SPINAL MUSCULAR ATROPHY; COST; ECONOMICS; GENETICS; PROCEDURES;

COSTS AND COST ANALYSIS; GENETIC THERAPY; HUMANS; MUSCULAR ATROPHY, SPINAL; OLIGONUCLEOTIDES, ANTISENSE;

EID: 85032510184     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2017.48     Document Type: Review

References (18)

1. Beltrão-Braga PC, Pignatari GC, Russo FB, Fernandes IR, Muotri AR. In-a-dish: induced pluripotent stem cells as a novel model for human diseases. Cytometry A 2013; 83: 11-17.
2. Naldini L. Gene therapy returns to centre stage. Nature 2015; 526: 351-360.
3. Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 2016; 388: 476-487.
4. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341: 1233158.
5. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388: 3017-3026.
6. Bishop KM. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases. Neuropharmacology 2017; 120: 56-62.
7. Sridharan K, Gogtay NJ. Therapeutic nucleic acids: current clinical status. Br J Clin Pharmacol. 2016; 82: 659-672.
8. Lundin KE, Gissberg O, Smith CI. Oligonucleotide therapies: the past and the present. Hum Gene Ther 2015; 26: 475-485.
9. Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 2015; 51: 157-167.
10. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010; 24: 1634-1644.
11. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008; 82: 834-848.
12. Passini MA, Bu J, Richards AM, Sardi SP, O'Riordan CR, Klinger KW et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011; 3: 72ra18.
13. Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006; 26: 1333-1346.
14. Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116: 2290-2296.
15. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011; 478: 123-126.
16. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012; 74: 1031-1044.
17. Zaghloul E, Gissberg O, Moreno P, Siggens L, Mattias H, Jørgensen A et al. CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. Nucleic Acids Res 2017; 45: 5153-5169.
18. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose escalation study. Lancet 2016; 388: 3017-3026.